Want to see TARA full AI Analyst Report?
Top Page
Protara Therapeutics
(NASDAQ:TARA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$4.00
▼(-26.47% Downside)
Action:Reiterated
Date:07/01/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and heavy negative free cash flow) despite a low-leverage balance sheet. Technicals also pressure the score, with the stock trading below all key moving averages. Valuation offers limited support due to negative earnings, and the recent increase in authorized shares adds incremental dilution risk.
Positive Factors
Low Leverage / Strong Equity Base
Very low leverage gives the company financial flexibility to fund R&D and absorb setbacks without interest burden. A materially larger equity base since 2023 improves solvency and supports additional financing options, reducing near-term liquidity crisis risk for a clinical-stage biotech.
Negative Factors
No Revenue / Recurring Losses
As a clinical-stage firm with essentially zero revenue, the company cannot self-fund operations and remains fully dependent on external capital. Persistent operating and net losses mean value creation hinges on successful clinical readouts or partnerships, raising binary outcome risk for investors.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Equity Base
Very low leverage gives the company financial flexibility to fund R&D and absorb setbacks without interest burden. A materially larger equity base since 2023 improves solvency and supports additional financing options, reducing near-term liquidity crisis risk for a clinical-stage biotech.
Read all positive factors
Protara Therapeutics (TARA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$229.88M
Dividend YieldN/A
Average Volume (3M)746.68K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue GrowthN/A
EPS Growth21.65%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.46
Shares Outstanding56,204,240
10 Day Avg. Volume836,161
30 Day Avg. Volume746,679
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.04
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.00Price Target Upside377.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.33
Revenue Forecast (FY)N/A
Protara Therapeutics Business Overview & Revenue Model
Company Description
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncolog...
How the Company Makes Money
null...
Protara Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -90.00K | -362.00K | 0.00 | -341.00K | 0.00 | 0.00 |
| EBITDA | -62.94M | -57.08M | -44.26M | -40.08M | -64.57M | -45.40M |
| Net Income | -63.31M | -57.44M | -44.60M | -40.42M | -65.95M | -47.25M |
Balance Sheet | ||||||
| Total Assets | 191.92M | 209.47M | 181.45M | 78.95M | 113.29M | 172.60M |
| Cash, Cash Equivalents and Short-Term Investments | 135.79M | 155.55M | 170.29M | 65.58M | 84.37M | 91.23M |
| Total Debt | 3.06M | 3.36M | 4.48M | 5.47M | 6.38M | 7.24M |
| Total Liabilities | 10.71M | 13.06M | 14.32M | 10.63M | 11.21M | 10.68M |
| Stockholders Equity | 181.21M | 196.41M | 167.13M | 68.32M | 102.08M | 161.91M |
Cash Flow | ||||||
| Free Cash Flow | -63.05M | -56.46M | -35.87M | -37.60M | -26.58M | -35.10M |
| Operating Cash Flow | -62.99M | -56.37M | -35.81M | -37.56M | -26.46M | -34.50M |
| Investing Cash Flow | -95.86M | -139.49M | 19.16M | 53.11M | 14.95M | -98.19M |
| Financing Cash Flow | 82.13M | 82.72M | 139.87M | -91.00K | -90.00K | -228.00K |
Protara Therapeutics Technical Analysis
Negative
5.44
Price Trends
4.44
Negative
4.94
Negative
5.33
Negative
Market Momentum
-0.05
Negative
47.79
Neutral
47.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TARA, the sentiment is Negative. The current price of 5.44 is above the 20-day moving average (MA) of 4.08, above the 50-day MA of 4.44, and above the 200-day MA of 5.33, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 47.79 is Neutral, neither overbought nor oversold. The STOCH value of 47.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TARA.
Protara Therapeutics Risk Analysis
Protara Therapeutics disclosed 62 risk factors in its most recent earnings report. Protara Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Protara Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $186.12M | 12.07 | 28.10% | ― | 27.80% | 268.45% | |
56 Neutral | $480.69M | -4.94 | -54.60% | ― | ― | -60.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $151.56M | -3.71 | -153.99% | ― | ― | 94.79% | |
49 Neutral | $220.96M | -2.57 | -137.99% | ― | 1033.89% | 36.35% | |
47 Neutral | $229.88M | -2.82 | -38.70% | ― | ― | 21.65% | |
42 Neutral | $21.79M | -0.42 | -217.27% | ― | ― | -74.39% |
* Healthcare Sector Average
TARA
Protara Therapeutics
4.12
0.97
30.79%
PLX
Protalix
2.33
0.90
62.94%
HURA
TuHURA Biosciences
2.28
-0.08
-3.39%
SKYE
Skye Bioscience
0.61
-3.08
-83.58%
OBIO
Orchestra BioMed Holdings
3.65
0.50
15.87%
ZURA
Zura Bio
5.39
4.10
317.83%
Protara Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Protara Therapeutics Announces Key Medical Leadership Transition
Neutral
Jun 29, 2026
On June 26, 2026, Protara Therapeutics, Inc. announced that Chief Medical Officer Leonardo Viana Nicacio, M.D., resigned from the company to pursue other opportunities, marking a leadership transition within its medical organization. The CMO respo...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Protara Therapeutics Stockholders Approve Governance and Share Increases
Positive
Jun 15, 2026
Protara Therapeutics held its Annual Meeting of Stockholders on June 12, 2026, where investors elected three Class III directors—Jesse Shefferman, Barry Flannelly and Cynthia Smith—to serve on the board until the 2029 annual meeting. S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.